title: Race to report: are vascular endothelial growth factor genetic polymorphisms associated with outcome in advanced breast cancer patients treated with Paclitaxel plus bevacizumab?
authors.forename: Min-Han
authors.initials: MH
authors.lastname: Tan
authors.forename: Tan
authors.initials: T
authors.lastname: Min-Han
authors.forename: Chuen Seng
authors.initials: CS
authors.lastname: Tan
authors.forename: Tan Chuen
authors.initials: TC
authors.lastname: Seng
authors.forename: Wei Yen
authors.initials: WY
authors.lastname: Lim
authors.forename: Lim Wei
authors.initials: LW
authors.lastname: Yen
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage; D020641:Polymorphism, Single Nucleotide; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D017239:Paclitaxel